Wright State University

CORE Scholar
Scholarship in Medicine - All Papers

Scholarship in Medicine

2020

Effect of HIV prevalence and Gender on Cardiovascular Disease
Deaths
Tanjeev Ahmad
Wright State University - Main Campus, ahmad.29@wright.edu

Follow this and additional works at: https://corescholar.libraries.wright.edu/scholarship_medicine_all
Part of the Cardiology Commons

Repository Citation
Ahmad, T. (2020). Effect of HIV prevalence and Gender on Cardiovascular Disease Deaths. Wright State
University. Dayton, Ohio.

This Article is brought to you for free and open access by the Scholarship in Medicine at CORE Scholar. It has been
accepted for inclusion in Scholarship in Medicine - All Papers by an authorized administrator of CORE Scholar. For
more information, please contact library-corescholar@wright.edu.

Effect of HIV prevalence and Gender on Cardiovascular Disease Deaths
Tanjeev Ahmad
Amber Todd, Office of Medical Education
Track
Scholarship in Medicine Final Report

☒ By checking this box, I indicate that my mentor has read and reviewed my draft
proposal prior to submission

Abstract
Objective: (State your objective). Methods: (Describe your methods). Results: (Provide your
results).
Cardiovascular disease is a widely diagnosed condition that can have many etiologies and factors
that changes its prognosis. This project was aimed at investigating two potential factors that
changes its prognosis: HIV status and gender. Data on HIV status was collected from NCHHSTP
AtlasPlus for all US states and territories and data on cardiovascular disease deaths and
corresponding gender was collected from Interactive Atlas of Heart Disease and Stroke for all
US states and territories. Using a linear regression test, a correlation was tested for between HIV
status and cardiovascular disease deaths for every US state/territory followed by a test between
gender and cardiovascular disease deaths for every US state/territory. The study did not yield
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significant results between HIV status and cardiovascular disease deaths, a rise in .006 deaths for
every case of HIV, however it did yield statistically significant data between gender and
cardiovascular disease deaths, 161 fewer deaths per thousand in females versus males.
Key Words: cardiovascular disease, HIV, mortality
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Introduction/Literature Review
Cardiovascular disease has been a significant diagnosis made in the United States due to how
drastically it affects the day to day life of the person diagnosed with it. It is also a diagnosis that
is being made more frequently due to its association with obesity and hypertension which are
concurrently on the rise. To minimize its prevalence, it is important to investigate what factors
are associated with cardiovascular disease; One possible factor that can be associated with
cardiovascular disease is HIV. In a study conducted on biventricular heart function on adults
with Human Immunodeficiency Virus (HIV) infection, a correlation was found between
echocardiograph detected ventricular wall deformation and having HIV 1. Therefore, there is
evidence that HIV status can possibly lead to subclinical myocardial dysfunction.
A separate study also found a positive correlation between HIV status and cardiovascular
disease, in the form of ischemic electrocardiography by gender 2. According to this study,
women who were HIV positive were at twice the risk of having myocardial ischemia compared
to men who were HIV positive. Therefore, it will be important to monitor HIV patients more
carefully according to gender due to an increased risk for cardiovascular disease for women. One
of the cardiovascular complications that can arise in HIV patients is a risk for atrial fibrillation
which can lead to thromboembolisms and consequent brain strokes 3. Therefore, HIV patients
had an increased risk of ischemic stroke and systemic embolism along with major bleeding as
cardiovascular complications compared to patients without HIV.
If a correlation is found between HIV and cardiovascular risk, a treatment plan needs to be
devised to provide patients with a way to minimize the severity of their cardiovascular disease.
One study investigated a possible treatment route by assessing the effectiveness of an 8 week
aerobic exercise program on heart rate variability in people living with HIV taking anti-retroviral

Ahmad 4
therapy (ART), the researchers were unable to conclude that aerobic exercise had an effect on
heart rate variability but were able to obtain data that suggested overall autonomic function
improved across time with aerobic exercise 4. While it has already been suggested that exercise
has positive effects on mortality in obesity and hypertension prognosis, due to their exacerbation
being major factors leading to cardiovascular disease, it is also a significant finding that aerobic
exercise can positively impact the prognosis of cardiovascular disease in HIV patients; thereby
providing emphasizing the role of aerobic exercise as a potential treatment route for patients with
cardiovascular disease and HIV. Another study investigated an alternative treatment plan by
studying immature platelet function (IPF) of HIV patients who were on ART. According to a
previous research study done, IPF was increased in HIV negative patients with cardiovascular
disease which was associated with adverse cardiovascular events, however patients with HIV on
ART showed lower immature platelet function 5. The study concluded that a reduction in IPF
could only be obtained with administration of ART in the absence of cardiovascular disease and
that the presence of cardiovascular disease hindered any significant reduction in IPF, however
the researchers of this study suggested a future investigation to be done to determine if an
increased IPF can be used as a biomarker for predicting adverse cardiovascular events in HIV
patients. If patients present with an enlarged IPF, this biomarker could serve as a protective
warning sign against a potential adverse cardiovascular event.

Hypothesis/Specific Aims/Research Questions
Numerous research data has suggested that HIV prevalence is associated and positively
correlated with cardiovascular disease deaths, but little has been done to suggest how HIV status
affects the outcome of cardiovascular disease. I hypothesize a positive correlation between HIV
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prevalence and deaths from cardiovascular disease by way of HIV exacerbating cardiovascular
disease thereby outlining a cause and effect. Additionally I hypothesize a difference in
cardiovascular disease prognosis between male and female gender.
Methods
Context/Protocol
I utilized data from human subjects that was already available on the CDC wonder public
data set.
Data Collection
In order to investigate the effect HIV status and gender has on cardiovascular disease
outcome, I collected data on 3 variables: HIV prevalence, gender, and cardiovascular disease
deaths in all US states and territories. HIV prevalence was available on the NCHHSTP AtlasPlus
data on HIV prevalence between 2014 and 2016 for ages 13 years and older for all races, sexes,
and transmission categories. I collected cardiovascular disease death data and the gender for the
corresponding data set on the Interactive Atlas of Heart Disease and Stroke for all US states and
territories. The three variables I will analyze will be number of cases of HIV in each US state or
dependent area compared to number of deaths due to cardiovascular disease in that same US
state or dependent area compared to gender.
Data Analysis
A linear regression test paired the HIV prevalence and cardiovascular disease deaths data to
assess for a correlation between HIV prevalence and cardiovascular disease deaths. A p-value of
less than .05 was considered statistically significant and suggested that HIV status has been
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observed to worsen the prognosis of cardiovascular disease. The linear regression test assessed
for a correlation between gender and cardiovascular disease deaths. The data was inputted such
that males had a numerical value of 1 and females had a numerical value of 2. A p-value of less
than .05 was again considered statistically significant and suggested that cardiovascular disease
is exacerbated by the gender given the higher numerical value: female, in this study.
Results
Table 1: Cardiovascular Disease Deaths, HIV Prevalence, and Gender descriptive
statistics
Category

Mean

Standard

Sample Size (N)

Deviation
Cardiovascular

441.07

120.45

112

HIV Prevalence

308.37

421.06

112

Gender

1.5

.50225

112

Disease Deaths

Table 1 lists the descriptive statistics given by the linear regression analysis. Of the 112
samples, the mean number of cardiovascular disease deaths was 441.07 per US state or
region. The mean number of HIV cases in each state or region was 308.37. Finally, the
mean value of gender was 1.5, between males having a value of 1 and females having a
value of 2, indicating equal representation of male and female sample data.
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Table 2: Correlations between Cardiovascular Disease Deaths, HIV Prevalence, and
Gender
Category

Cardiovascular

HIV Prevalence

Gender

1.00

.27

-.68

HIV Prevalence

.27

1.00

-.37

Gender

-.68

-.37

1.00

Disease Deaths
Cardiovascular
Disease Deaths

Table 2 states the correlation values obtained by the linear regression analysis.
Cardiovascular disease deaths had a correlation of .27 with HIV prevalence and a -.68
correlation with Gender. HIV prevalence had a -.37 correlation with Gender.

Table 3: Linear Regression Results for HIV Prevalence and Gender vs Cardiovascular
Disease Deaths
Category

B value

Standard Error

Significance value
(alpha=.05)

HIV Prevalence

.006

.022

.77

Gender

-161.85

18.05

.00

Table 2 lists the B values obtained by the linear regression analysis. HIV prevalence was
not shown to have a statistically significant value at .006. Gender was shown to have a
statistically significant value of -161.85.
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Discussion
Although Table 2 demonstrates a positive correlation between HIV prevalence and
cardiovascular disease deaths, the correlation is small and the B value of .006 is deemed
statistically insignificant by the set alpha value of .05. The minor interpretation to be made is
that for every new case of HIV, the mean number of cardiovascular disease deaths that rise is
approximately 0.006 per thousand. The more significant finding of this study was highlighted
by B value of the gender vs cardiovascular disease deaths analysis. Using an alpha of 0.05, it
was found to be statistically significant with a value of -161.85. This indicated that for every
point increase in gender, going from male to female, the number of cardiovascular disease
deaths decreased by approximately 161.85 cases per thousand. This result contradicts much
of the literature that suggest women having a higher risk of developing cardiovascular
disease than men such as in the earlier mentioned study in which HIV positive women had
twice the likelihood of HIV positive men in developing a worse cardiovascular outcome 2.
Upon further investigation however, there has been evidence to suggest that estrogen can be
attributed as the protective factor in women. A study conducted on the gender differences in
coronary heart disease found that women tend to develop cardiovascular disease 7 to 10 years
later than men but women who had an endogenous estrogen deficiency had a sevenfold
increase in coronary artery disk risk. Estrogen was claimed to have a protective factor against
heart disease due to its regulatory effect on lipids, inflammatory markers, and the coagulant
system in addition to its direct vasodilatory effects through the alpha and beta receptors in the
vessel wall 6. An additional study attributed estrogen’s cardioprotective results to its
interaction with the E2 receptor. In this study, heart failure and ischemic heart injury were
linked to bioenergetic abnormalities such as mitochondrial homeostasis. The estrogen
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activated E2 receptor can trigger transcriptional changes in nuclear and mitochondrial genes
to positively influence mitochondrial function and cell survival thereby offering cardioprotection 7. Although this is a preliminary finding, if further investigation confirms the
protective role of estrogen, then the potential exists for artificial estrogen to stimulate the E2
receptor and protect the population with risk factors for cardiovascular disease or those with
a bad prognosis of cardiovascular disease.
Conclusion
Although the results of this study conclude that HIV does not affect cardiovascular disease
prognosis and that women have a more favorable prognosis with cardiovascular disease
prognosis, the design of the study faces limitations thereby preventing these results from
being definitive. The linear regression test used means that the data used pertained to an
entire state rather than a single person. Therefore, the same patients who were diagnosed with
HIV were not necessarily the same patients who died from or survived cardiovascular disease
or were even diagnosed with it. This means that there could still be a causal effect between
HIV and cardiovascular disease, as the literature suggest. Furthermore, gender may also not
affect cardiovascular disease due to the same limitation of a linear regression test. Future
studies should be conducted in order to further investigate these potential relationships
between HIV with cardiovascular disease and gender with cardiovascular disease. Much of
the literature seems to suggest an association between HIV and cardiovascular disease, and if
a true causal relationship can be established, it may necessitate cardiovascular disease
preventative measures. Additionally, if a relationship between gender and cardiovascular
disease can be causally established, the vulnerable gender can also be given subsequent
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cardioprotective measures. With these additional steps, numerous cases of cardiovascular
disease can be prevented.
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